Treating lung cancer is more precise than ever, thanks to biomarker testing, which gives clinicians a better understanding of individual’s tumors.
Biomarker Testing in Lung Cancer Continues to Improve Outcomes, Move the Field Forward
Years ago, many patients with lung cancer were treated the same, as there was limited knowledge about the disease and limited therapies to treat it. Then, biomarker testing brought precision...
On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34417059/
Non-small cell lung carcinoma (NSCLC) is a leading cause of cancer death. Approximately one-third of patients with NSCLC have a KRAS mutation. KRAS G12C , the most common mutation, is...
-
Alireza Mirmiran4yrI am very open to a combination treatment approach, but I would like to see some more prospective data first.
-
KRAS Oncogene Connect4yrWhat are your thoughts about combining KRAS inhibitors with other agents?
Show More Comments
Transition From Distinct Types of KRAS Mutation-Harboring Multifocal Lung Adenocarcinoma to Rhabdoid Tumor: A Longitudinal Follow-Up - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34432771/
BACKGROUND Rhabdoid tumor (RT) of the lung is a rare and aggressive malignancy. The origin of and the mutation responsible for RT are entirely unknown. The distinction between RT associated...
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34430361/
1 Department of Medical Oncology, Changzheng Hospital, Naval Medical University, Shanghai, China. 2 Department of Respiratory Medicine, The Second Affiliated Hospital of Zhejiang University School of Medicine at Bingjiang, Hangzhou,...
a group of researchers from Memorial Sloan Kettering Cancer Center reported in the journal Science Translational Medicine that a specific pattern, or “signature,” of markers on immune cells in the blood is a likely biomarker of response to checkpoint immunotherapy. Within this immune signature, a molecule LAG-3 provided key information...
MSK Study Identifies Biomarker That May Help Predict Benefits of Immunotherapy
Source : https://www.mskcc.org/news/msk-study-identifies-biomarker-may-help-predict-benefits-immunotherapy
In recent years, immune-based treatments for cancer have buoyed the hopes of doctors and patients alike. Drugs called immune checkpoint inhibitors have provided lifesaving benefits to a growing list of...